Pfizer Terminates Torcetrapib Program
Company will investigate whether an increased risk of mortality is a class effect of CETP inhibitors.
More from Archive
More from Pink Sheet
• By
After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.
• By
Generic drug industry representatives applauded the FDA decision to bring back key staff in the Office of Generic Drugs that were laid off earlier this year.
• By
The White House is directing the Health and Human Services Department to replenish stockpiles of active pharmaceutical ingredients for “especially critical” medicines.